Canaccord Genuity Maintains Buy on Y-mAbs Therapeutics, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Bill Maughan maintains a Buy rating on Y-mAbs Therapeutics (NASDAQ:YMAB) with a $26 price target.
August 13, 2024 | 4:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Bill Maughan maintains a Buy rating on Y-mAbs Therapeutics with a $26 price target.
The reaffirmation of a Buy rating and a $26 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100